Can you provide the last earnings date for ANNOVIS BIO?
ANNOVIS BIO (ANVS) last reported earnings on 3/13/2026.
NYSE:ANVS • US03615A1088
Past quarterly earnings results for ANNOVIS BIO (ANVS), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | -0.39 | -0.35 | -11.37% | 9.30% | - | - | ||
| Q3 2025 | -0.37 | -0.31 | -18.93% | 61.86% | - | - | ||
| Q2 2025 | -0.32 | -0.41 | 22.06% | - | - | - | ||
| Q1 2025 | -0.32 | -0.36 | 11.97% | -220.00% | - | - | ||
| Q4 2024 | -0.43 | -0.34 | -27.55% | 80.80% | - | - | ||
| Q3 2024 | -0.97 | -0.54 | -80.79% | 40.49% | - | - | ||
| Q2 2024 | -0.32 | -0.64 | 50.15% | 70.09% | - | - | ||
| Q1 2024 | -0.10 | -0.81 | 87.72% | 91.60% | - | - | ||
| Q4 2023 | -2.24 | -1.33 | -68.35% | -489.47% | - | - | ||
| Q3 2023 | -1.63 | -1.11 | -46.56% | -75.27% | - | - | ||
| Q2 2023 | -1.07 | -1.16 | 8.12% | - | - | - | ||
| Q1 2023 | -1.19 | -0.34 | -249.30% | -65.28% | - | - | ||
| Q4 2022 | -0.38 | -1.07 | 64.61% | 49.33% | - | - | ||
| Q3 2022 | -0.93 | -1.03 | 10.02% | -165.71% | - | - | ||
| Q2 2022 | -1.07 | -0.66 | -62.64% | -214.71% | - | - | ||
| Q1 2022 | -0.72 | -0.59 | -21.70% | -56.52% | - | - | ||
| Q4 2021 | -0.75 | -0.26 | -194.12% | -359.56% | - | - | ||
| Q3 2021 | -0.35 | -0.45 | 22.01% | -133.33% | - | - | ||
| Q2 2021 | -0.34 | -0.38 | 9.91% | - | - | - | ||
| Q1 2021 | -0.46 | - | - | - | - | |||
| Q4 2020 | -0.16 | - | - | - | - | |||
| Q3 2020 | -0.15 | -0.15 | 1.96% | - | - | - | ||
| Q2 2020 | -0.34 | -0.15 | -122.22% | - | - | - | ||
| Q1 2020 | - | - | - | - |
Notes
ANNOVIS BIO (ANVS) last reported earnings on 3/13/2026.
ANNOVIS BIO (ANVS) missed EPS estimates and missed revenue estimates in the most recent quarter.
In the last 4 quarters, ANNOVIS BIO (ANVS) has beaten EPS estimates in 2 out of 4 releases.